Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
U.S. FDA
Pharma
Regulatory tracker: FDA rejects Dynavax's hep B add-on filing
Here, we're tracking the regulatory progress of in-market products, including expansions into key geographies and new indications.
Fraiser Kansteiner
,
Eric Sagonowsky
,
Angus Liu
,
Kevin Dunleavy
,
Zoey Becker
May 15, 2024 9:45am
Biogen, Eisai kick off rolling FDA submission for subQ Leqembi
May 14, 2024 7:51pm
House lawmaker brings FDA into security crackdown on China
May 8, 2024 11:05am
Dupixent COPD delay possible, Eylea down 2%, Regeneron says
May 2, 2024 12:00pm
Sanofi is going all in on Dupixent's next potential nod in COPD
Apr 25, 2024 12:37pm
Argenx gears up to launch Vyvgart in next potential indication
Apr 16, 2024 2:24pm